COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
Author: Serena Colafrancesco,Cristiano Alessandri,Fabrizio Conti,Roberta Priori
Publication: Autoimmunity Reviews
Publisher:Elsevier
Date:July 2020
Author: Serena Colafrancesco,Cristiano Alessandri,Fabrizio Conti,Roberta Priori
Publication: Autoimmunity Reviews
Publisher:Elsevier
Date:July 2020
Due to the capacity of iron chelation to taper the inflammatory response through a reduction of ROS production and to promote an anti-viral activity, the utility of this therapeutic approach in patients with SARS-CoV-2 infection has been recently addressed [24]. A clinical trial on the use of Desferal (Deferoxamine, a medication able to bind iron in case of “iron overdose”) is currently ongoing in IRAN in patients with mild to severe COVID-19 infection (NCT04333550).